Abstract:Christopher W. Course ^ , Sarah J. Kotecha ^ , Sailesh Kotecha ^ Department of Child Health, School of Medicine, Cardiff University, Cardiff, UK ^ ORCID: Christopher W. Course, 0000-0002-7789-2057; Sarah J. Kotecha, 0000-0001-5640-0300; Sailesh Kotecha, 0000-0003-3535-7627. Comment on: Urs RC, Evans DJ, Bradshaw TK, et al . Inhaled corticosteroids to improve lung function in children (aged 6-12 years) who were bornvery preterm (PICSI): a randomised, double-blind, placebo-controlled trial. Lancet Child Adolesc Health 2023;7:567-76. Keywords: Prematurity; bronchopulmonary dysplasia (BPD); spirometry; inhaled corticosteroids; bronchodilators Submitted Oct 12, 2023. Accepted for publication Dec 18, 2023. Published online Jan 15, 2024. doi: 10.21037/tp-23-505 Preterm birth remains a major world-wide health problem (1). Whilst mortality is decreasing especially at the immature gestations, it is apparent that survivors are at increased risk of life-long morbidity including from adverse respiratory outcomes. Our recently updated systematic review demonstrated that, despite advances in neonatal care over the last thirty years, lung function impairments are significant in preterm-born children, adolescents and adults including in those with and without the neonatal lung disease bronchopulmonary dysplasia [BPD, also known as chronic lung disease (CLD) of prematurity] (2). Notably, deficits in lung function are also observed in late preterm-born children who traditionally have not been considered as being at risk of long-term respiratory morbidity (3). The recent guidelines for management of BPD after discharge from the neonatal unit from both the American Thoracic Society (ATS) (4) and European Respiratory Society (ERS) (5) acknowledged the paucity of evidence to guide the long-term, post-discharge management of individuals with a neonatal history of BPD, highlighting the need for studies to assess treatment of prematurity-associated lung disease (PLD). The Respiratory Health Outcomes in Neonates (RHiNO) study has recently demonstrated that there are multiple spirometry phenotypes of PLD, including both fixed and reversible prematurity-associated obstructive lung disease (POLD), prematurity-associated preserved ratio with impaired spirometry (pPRISm) and dysanaptic spirometry patterns, which are differentially associated with early- and current-life factors, including BPD (6). There is an increasing concern that PLD may predispose an individual to the premature development of chronic obstructive pulmonary disease (COPD) in early adulthood (7,8), with implications for quality of life and life expectancy if lung function deficits continue to track into adulthood. Whilst much research focus has concentrated on the mechanism of respiratory morbidity in those with a history of BPD (9,10), it is increasingly apparent that there is a population of preterm-born subjects who develop PLD despite not having had a diagnosis of BPD in the neonatal period (3,11), with impaired spirometry, altered respiratory mechanics and reduced gas diffusion capacity (12). Furthermore, other early life risk factors such as gestational immaturity and intrauterine growth restriction are also strongly associated with later adverse respiratory outcomes (13). Many children with PLD are often given a diagnostic label of asthma (14). However, the mechanisms underlying PLD are likely to be different to those observed in classical asthma which is often predominated by eosinophilic airway inflammation (15) and are only now beginning to be investigated (16-18). Until recently, there have been two previous studies examining inhaled therapies in the management of children with PLD, both studying participants from the pre-/peri-surfactant era ( Table 1 ). Chan et al. performed a double-blind, placebo-controlled cross-over study of fifteen low birth weight children, aged eight years who were born with a mean gestational age of 30.5 weeks. All were born before the routine use of exogenous pulmonary surfactant replacement. The children received twice daily 200 μg of inhaled beclomethasone dipropionate for four weeks or placebo in a cross-over study. There was no significant effect on peak expiratory flow rate (PEFR), forced expiratory volume in one second (FEV 1 ) or airway hyper-responsiveness following treatment (19). In the other study occurring during introduction of exogenous surfactant treatment, Pelkonen et al. studied eighteen children (median gestation at birth of 28 weeks and median of age 10.1 years) who had evidence of reversibility of airway obstruction as assessed by response to short-acting β 2 -agonists. These children received inhaled budesonide (0.8 mg/m 2 /day for 1 month followed by 0.4 mg/m 2 /day for 3 months) over a four-month period. No significant differenc -Abstract Truncated-

Relationships of Severity of Bronchopulmonary Dysplasia with Adverse Neurodevelopmental Outcomes and Poor respiratory Function at 7-8 Years of Age

Risk Factors for Bronchopulmonary Dysplasia Infants with Respiratory Score Greater Than Four: a Multi-Center, Prospective, Longitudinal Cohort Study in China

Home Oxygen Use and 1-Year Outcome among Preterm Infants with Bronchopulmonary Dysplasia Discharged from a Chinese Regional NICU

[A Comparison of the Clinical Diagnosis and Outcome in Preterm Infants with Bronchopulmonary Dysplasia under Two Different Diagnostic Criteria].

Clinical Features and Prognosis of Bronchopulmonary Dysplasia Complicated by Pulmonary Hypertension in Preterm Infants

Association between bronchopulmonary dysplasia severity and its risk factors and long-term outcomes in three definitions: a historical cohort study

Validation of the National Institutes of Health Consensus Definition of Bronchopulmonary Dysplasia

Bronchopulmonary Dysplasia: A Five-Year Retrospective Cohort Study on Differences in Clinical Characteristics and Morbidities According to Severity Grading

Neurodevelopmental outcomes of infants with bronchopulmonary dysplasia

Severity of Bronchopulmonary Dysplasia Among Very Preterm Infants in the United States

Pulmonary function and bronchopulmonary dysplasia classification: insights from the Spanish Registry

Impact of severity and age with variable definitions of bronchopulmonary dysplasia on neurodevelopmental outcomes

Outcomes of and factors associated with the development of bronchopulmonary dysplasia with pulmonary hypertension in very low birth weight infants: A retrospective study in a medical center

Factors of late respiratory support or oxygen weaning in infants with bronchopulmonary dysplasia

Diagnosis and management of bronchopulmonary dysplasia

Prognosis of Bronchopulmonary Dysplasia in Preterm Infants: a Follow-Up During Infancy

Achieved oxygen saturations and risk for bronchopulmonary dysplasia with pulmonary hypertension in preterm infants

Evolving treatment for prematurity-associated lung disease

Early Arrest Of Lung Development And Its Impact On Childrens Airway Resistance

Analysis of Incidence and Follow-Up of Bronchopulmonary Dysplasia in Premature Infants

Predischarge death or lung transplantation in tracheostomy and ventilator dependent grade 3 bronchopulmonary dysplasia